Recombinant Human NAGLU Protein, CF (Catalog # 7096-GH) degrades heparan sulfate by hydrolysis of terminal GlcNAc resides in N-acetyl-alpha-D-glucosaminides.
Recombinant Human NAGLU Protein, CF (Catalog # 7096-GH) is measured by its ability to hydrolyze 4-Nitrophenyl-N-acetyl-alpha -D-glucosaminide.
2 μg/lane of Recombinant Human NAGLU Protein (Catalog # 7096-GH) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 70-95 ...read more
Measured by its ability to hydrolyze 4-Nitrophenyl-N-acetyl-alpha -D-glucosaminide. The specific activity is >900 pmol/min/μg, as measured under the decribed conditions.
Source
Chinese Hamster Ovary cell line, CHO-derived human alpha-N-acetylglucosaminidase/NAGLU protein Met1-Trp743, with a C-terminal 6-His tag
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Endotoxin Note
<1.0 EU per 1 μg of the protein by the LAL method.
Applications/Dilutions
Dilutions
Enzyme Activity
Theoretical MW
81 kDa. Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
SDS-PAGE
70-95 kDa, reducing conditions
Publications
Read Publications using 7096-GH in the following applications:
Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
6 months from date of receipt, -20 to -70 °C as supplied.
3 months, -20 to -70 °C under sterile conditions after opening.
Buffer
Supplied as a 0.2 μm filtered solution in Tris and NaCl.
Purity
>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
Assay Procedure
Assay Buffer: 0.1 M Sodium Citrate, 0.25 M NaCl, pH 4.5
Recombinant Human alpha ‑N‑acetylglucosaminidase/NAGLU (rhNAGLU) (Catalog # 7096-GH)
Substrate: 4-Nitrophenyl-N-acetyl-alpha -D-glucosaminide (Sigma, Catalog # N-8759), 5 mM stock in deionized water
NaOH, 0.2 M stock in deionized water
96-well Clear Plate (Costar, Catalog # 92592)
Plate Reader (Model: SpectraMax Plus by Molecular Devices) or equivalent
Dilute rhNAGLU to 3 ng/μL in Assay Buffer.
Dilute Substrate to 3 mM in Assay Buffer.
In a plate combine 50 μL of rhNAGLU and 50 μL of 3 mM Substrate. Include a Substrate Blank containing 50 μL Assay Buffer and 50 μL of 3 mM Substrate.
Seal plate and incubate at 37 °C for 20 minutes.
Add 100 μL of 0.2 M NaOH to each well to stop the reaction and develop the color.
Read absorbance in endpoint mode at 402 nm.
Calculate specific activity:
Specific Activity (pmol/min/µg) =
Adjusted Abs* (OD) x well volume (L) x 1012 pmol/mol
Inc. time (min) x epsilon ** (M-1cm-1) x path corr.*** (cm) x amount of enzyme (µg)
*Adjusted for Substrate Blank **Using the extinction coefficient 17700 M-1cm-1 ***Using the path correction 0.6 cm
Per Well:
rhNAGLU: 0.150 μg
Substrate: 750 μM
Notes
This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.
Alternate Names for Recombinant Human NAGLU Protein, CF
alphaNacetylglucosaminidase
alpha-N-acetylglucosaminidase
EC 3.2.1.50
MPS3B
MPS-IIIB
N-acetyl-alpha-glucosaminidase
N-acetylglucosaminidase, alpha
NAG
NAGalpha-N-acetylglucosaminidase
NAGLU
UFHSD
UFHSD1
Background
Human lysosomal alpha -N-acetylglucosaminidase is a hydrolase that catalyses the removal of terminal alpha ‑N‑acetylglucosamine residues from heparan sulfate and heparin (1). Defects in this gene are the cause of mucopolysaccharidosis type IIIB (MPS‑IIIB), also known as Sanfilippo syndrome B (2, 3, 4). Mucopolysaccharidosis types IIIA, C, and D are caused by mutations in other genes involved in the lysosomal degradation of heparan sulfate. Continuous lysosomal accumulation of heparan sulfate results in the clinical onset of disease, which is typified by severe central nervous system degeneration (5). Mucopolysaccharidosis type III differs from other mucopolysaccharidoses in that patients usually exhibit mild somatic changes with minimal skeletal abnormalities (6).
Yogalingam, G. et al. (2000) Biochim. Biophy. Acta 1502:415.
Zhao, H.G. et al. (1996) Proc. Natl. Acad. Sci. U.S.A. 93:6101.
Schmidtchen, A. et al. (1998) Am. J. Hum. Genet. 62:64.
Weber, B. et al. (1999) Eur. J. Hum. Genet. 7:34.
Beesley, C.E. et al. (2005) J. Inherit. Metab. Dis. 28:759.
Yogalingam, G. and Hopwood, J.J. (2001) Hum. Mutat. 18:264.
Reviews for alpha-N-acetylglucosaminidase/NAGLU (7096-GH) (0)
There are no reviews for alpha-N-acetylglucosaminidase/NAGLU (7096-GH).
By submitting a review you will receive an Amazon e-Gift Card or Novus Product Discount.
Review with no image -- $10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen
Review with an image -- $25/€18/£15/$25 CAD/¥150 Yuan/¥2500 Yen
FAQs for alpha-N-acetylglucosaminidase/NAGLU (7096-GH) (0)
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
=
÷
Review this Product
Be the first to review our Recombinant Human NAGLU Protein, CF and receive a gift card or discount.